Benefits of PARP Inhibitor Use in Breast Cancer
PARP Inhibitors Improve Outcomes, QOL in Breast Cancer
Not only are PARP inhibitors proving to be an efficacious treatment for patients with metastatic breast cancer, but they're also improving quality of life, too.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
